CoChat

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

Bailey, C. J., Morales Villegas, E. C., Woo, V., Tang, W., Ptaszynska, A., List, J. F. · 2015 · Diabetic Medicine
Cited by 154

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: To assess initial pharmacotherapy of Type 2 diabetes with the sodium‐glucose cotransporter‐2 inhibitor dapagliflozin. Methods: This double‐blind, placebo‐controlled trial, randomly allocated people with Type 2 diabetes aged 18–77 years and inadequate glycaemic control on diet and exercise [HbA 1c 53–86 mmol/mol (7.0–10.0%)] to receive placebo (n = 75) or dapagliflozin monotherapy 2.5 mg (n = 65), 5 mg (n = 64) or 10 mg (n = 70) once daily in the morning. After 24 weeks, low‐dose double‐blind metformin 500 mg/day was added to the placebo group regimen (placebo+low‐dose metformin group). Changes in HbA 1c level, fasting plasma glucose and body weight, as well as adverse events, were assessed over 102 weeks. Results: Of the 274 participants randomized, 167 completed the study (60.9%). At 102 weeks, significant differences vs placebo+low‐dose metformin with dapagliflozin 5 and 10 mg were observed for HbA 1c (−5.8 mmol/mol [−0.53%], P = 0.018; and −4.8 mmol/mol [−0.44%], P = 0.048), respectively); and for FPG (−0.69 mmol/L, P = 0.044; and −1.12 mmol/l, P = 0.001, respectively). For body weight, the difference between the dapagliflozin 10‐mg group and the placebo+low‐dose metformin group was significant (−2.60 kg; P = 0.016). Hypoglycaemic events were uncommon, with rates of 5.3% for placebo+low‐dose metformin group and 0–4.6% for the dapagliflozin groups. Genital infections and urinary tract infections were more common in the dapagliflozin groups than in the placebo+low‐dose metformin group. Conclusions: Dapagliflozin as monotherapy in treatment‐naïve people with early Type 2 diabetes improved glycaemic control and reduced weight without increasing hypoglycaemia over 102 weeks. Dapagliflozin may provide an alternative initial pharmacotherapy in such people.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12624

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 154

Metadata

Authors
Bailey, C. J., Morales Villegas, E. C., Woo, V., Tang, W., Ptaszynska, A., & List, J. F.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2014-11-22
Volume
32
Issue
4
Pages
531-541
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2097168611
Cited by
154
References
6
FWCI
8.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial. https://app.cochat.ai/papers/10.1111/dme.12624
The paper
Bailey, C. J., Morales Villegas, E. C., Woo, V., Tang, W., Ptaszynska, A., & List, J. F. (2015). Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial. Diabetic Medicine. https://doi.org/10.1111/dme.12624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.